AR033430A1 - Derivados de alcoxicarbonilamino tetrazolil fenilo o acido alcoxicarbonilamino benzoico, su uso, un proceso para su preparacion y composiciones farmaceuticas que los comprenden - Google Patents
Derivados de alcoxicarbonilamino tetrazolil fenilo o acido alcoxicarbonilamino benzoico, su uso, un proceso para su preparacion y composiciones farmaceuticas que los comprendenInfo
- Publication number
- AR033430A1 AR033430A1 ARP020100716A ARP020100716A AR033430A1 AR 033430 A1 AR033430 A1 AR 033430A1 AR P020100716 A ARP020100716 A AR P020100716A AR P020100716 A ARP020100716 A AR P020100716A AR 033430 A1 AR033430 A1 AR 033430A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- cyano
- halogen
- so2r
- nitro
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000003545 alkoxy group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010030113 Oedema Diseases 0.000 abstract 1
- 108091006335 Prostaglandin I receptors Proteins 0.000 abstract 1
- 208000026895 Vascular hypotensive disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- -1 cyano, nitro, phenyl Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003180 prostaglandins Chemical class 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 210000001635 urinary tract Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/26—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
- C07C271/28—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring to a carbon atom of a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C07D307/80—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Compuestos que comprende la formula general (1), en donde: G1 se selecciona de los grupos a, b1 y b2; A se selecciona del grupo consistente en fenilo, piridinilo, pirimidinilo, piridazinilo, pirazinilo, y tienilo, todos opcionalmente sustituidos con alquilo inferior, halogeno, halogenoalquilo, alcoxilo, ciano, nitro, -SO2R', -NR'SO2R'', -SO2NR'R'', -NR'R'', o -COR'; R' y R'' son cada uno independientemente hidrogeno o alquilo inferior; G2 se selecciona del grupo representado por las formulas c, d, e y f; R1 y R2 son independientemente en cada caso, seleccionados del grupo consistente en hidrogeno, alquilo inferior, halogeno, halogenoalquilo, -NR'R'', -OR', -NR'SO2R'', -SO2R', -SO2NR'R'', -COR', ciano, nitro, fenilo que está opcionalmente sustituido con halogeno, alquilo inferior, ciano, nitro, o alcoxilo, y heteroarilo que está opcionalmente sustituido con halogeno, alquilo inferior, ciano, nitro o alcoxilo; y en donde R' y R'' son tal como se han definido anteriormente; o R1 y R2, si son adyacentes, junto con los carbonos a que están unidos pueden formar un anillo aromático, opcionalmente sustituido con uno o dos sustituyentes seleccionados del grupo consistente en alquilo inferior, halogeno, ciano, y alcoxilo inferior; y n es un numero entero seleccionado de 0, 1, 2, y 3; o isomeros individuales, mezclas racémicas o no racémicas de isomeros, o sales o solvatos farmacéuticamente aceptables de los mismos. Composiciones farmacéuticas que contienen dichos compuestos, su uso como agentes terapéuticos, y los métodos de la preparacion de los mismos. Los compuestos de formula (1) son antagonistas de los receptores IP de prostaglandinas y por lo tanto son utiles en el tratamiento de por ejemplo enfermedades asociadas con el tracto urinario, dolor, inflamacion, estados respiratorios, formacion de edema, o enfermedades hipotensivas vasculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27287201P | 2001-03-02 | 2001-03-02 | |
| US31255901P | 2001-08-15 | 2001-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR033430A1 true AR033430A1 (es) | 2003-12-17 |
Family
ID=26955795
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020100716A AR033430A1 (es) | 2001-03-02 | 2002-02-28 | Derivados de alcoxicarbonilamino tetrazolil fenilo o acido alcoxicarbonilamino benzoico, su uso, un proceso para su preparacion y composiciones farmaceuticas que los comprenden |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6903086B2 (es) |
| EP (1) | EP1379516B1 (es) |
| JP (1) | JP4018985B2 (es) |
| KR (1) | KR100559015B1 (es) |
| CN (1) | CN1256334C (es) |
| AR (1) | AR033430A1 (es) |
| AT (1) | ATE309994T1 (es) |
| AU (1) | AU2002253061B2 (es) |
| BR (1) | BR0207795A (es) |
| CA (1) | CA2438737A1 (es) |
| DE (1) | DE60207399T2 (es) |
| ES (1) | ES2252443T3 (es) |
| MX (1) | MXPA03007865A (es) |
| PA (1) | PA8540601A1 (es) |
| PE (1) | PE20020905A1 (es) |
| WO (1) | WO2002070500A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0218876D0 (en) * | 2002-08-13 | 2002-09-25 | Merck Sharp & Dohme | Therapeutic agents |
| EP1596858A1 (en) * | 2003-02-14 | 2005-11-23 | Medical Research Council | Ip receptor antagonists for the treatment of pathological uterine conditions |
| GB0503056D0 (en) * | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
| HUE025137T2 (en) * | 2007-08-21 | 2016-01-28 | Senomyx Inc | Compositions are bitter taste blocking (blocking) compounds |
| US8076491B2 (en) | 2007-08-21 | 2011-12-13 | Senomyx, Inc. | Compounds that inhibit (block) bitter taste in composition and use thereof |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| US9295665B2 (en) | 2013-03-12 | 2016-03-29 | Allergan, Inc. | Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors |
| US9321745B2 (en) | 2013-03-12 | 2016-04-26 | Allergan, Inc. | Inhibition of neovascularization by inhibition of prostanoid IP receptors |
| CN106496036A (zh) * | 2016-09-29 | 2017-03-15 | 福建天富生物科技发展有限公司 | 一种抗凝血药物中间体5‑甲氧基‑2‑硝基苯甲酸的制备方法 |
| EP3680232B1 (en) | 2017-08-07 | 2024-12-11 | Amenis Biosciences, Inc. | Novel anthranilic acid-based compound, and pin1 inhibitor, therapeutic agent for inflammatory diseases and therapeutic agent for cancer that use the same |
| EP3746134A1 (en) | 2018-02-02 | 2020-12-09 | Maverix Oncology, Inc. | Small molecule drug conjugates of gemcitabine monophosphate |
| CN108774183A (zh) * | 2018-08-03 | 2018-11-09 | 成都苑东生物制药股份有限公司 | 一种乙二醇类化合物的制备方法 |
| EP4119138A1 (en) * | 2021-07-12 | 2023-01-18 | Universität Hamburg | Dhodh inhibitors and their use as antiviral agents |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6174905B1 (en) | 1996-09-30 | 2001-01-16 | Mitsui Chemicals, Inc. | Cell differentiation inducer |
| US5998424A (en) | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| US6184242B1 (en) | 1997-09-04 | 2001-02-06 | Syntex Usa (Llc) | 2-(substituted-phenyl)amino-imidazoline derivatives |
| US6320078B1 (en) | 1998-07-24 | 2001-11-20 | Mitsui Chemicals, Inc. | Method of producing benzamide derivatives |
| US6342516B1 (en) | 1998-07-31 | 2002-01-29 | Nippon Soda Co., Ltd. | Phenylazole compounds, process for producing the same and drugs for hyperlipemia |
| KR100523119B1 (ko) | 2000-03-16 | 2005-10-20 | 에프. 호프만-라 로슈 아게 | Ｉｐ 길항제로서의 카복실산 유도체 |
-
2002
- 2002-02-25 BR BR0207795-7A patent/BR0207795A/pt not_active IP Right Cessation
- 2002-02-25 WO PCT/EP2002/001943 patent/WO2002070500A1/en not_active Ceased
- 2002-02-25 JP JP2002569820A patent/JP4018985B2/ja not_active Expired - Fee Related
- 2002-02-25 CA CA002438737A patent/CA2438737A1/en not_active Abandoned
- 2002-02-25 MX MXPA03007865A patent/MXPA03007865A/es active IP Right Grant
- 2002-02-25 AT AT02722127T patent/ATE309994T1/de not_active IP Right Cessation
- 2002-02-25 KR KR1020037011543A patent/KR100559015B1/ko not_active Expired - Fee Related
- 2002-02-25 AU AU2002253061A patent/AU2002253061B2/en not_active Ceased
- 2002-02-25 EP EP02722127A patent/EP1379516B1/en not_active Expired - Lifetime
- 2002-02-25 CN CNB028058704A patent/CN1256334C/zh not_active Expired - Fee Related
- 2002-02-25 DE DE60207399T patent/DE60207399T2/de not_active Expired - Fee Related
- 2002-02-25 ES ES02722127T patent/ES2252443T3/es not_active Expired - Lifetime
- 2002-02-26 PA PA20028540601A patent/PA8540601A1/es unknown
- 2002-02-28 AR ARP020100716A patent/AR033430A1/es unknown
- 2002-02-28 PE PE2002000168A patent/PE20020905A1/es not_active Application Discontinuation
- 2002-03-01 US US10/087,034 patent/US6903086B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA03007865A (es) | 2003-12-04 |
| US6903086B2 (en) | 2005-06-07 |
| WO2002070500A1 (en) | 2002-09-12 |
| US20020165235A1 (en) | 2002-11-07 |
| ES2252443T3 (es) | 2006-05-16 |
| KR20040023591A (ko) | 2004-03-18 |
| JP2004529899A (ja) | 2004-09-30 |
| BR0207795A (pt) | 2004-03-23 |
| KR100559015B1 (ko) | 2006-03-10 |
| DE60207399D1 (de) | 2005-12-22 |
| CN1527824A (zh) | 2004-09-08 |
| ATE309994T1 (de) | 2005-12-15 |
| AU2002253061B2 (en) | 2005-04-07 |
| CA2438737A1 (en) | 2002-09-12 |
| PE20020905A1 (es) | 2002-10-19 |
| CN1256334C (zh) | 2006-05-17 |
| JP4018985B2 (ja) | 2007-12-05 |
| EP1379516B1 (en) | 2005-11-16 |
| DE60207399T2 (de) | 2006-08-03 |
| PA8540601A1 (es) | 2002-09-30 |
| EP1379516A1 (en) | 2004-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR033430A1 (es) | Derivados de alcoxicarbonilamino tetrazolil fenilo o acido alcoxicarbonilamino benzoico, su uso, un proceso para su preparacion y composiciones farmaceuticas que los comprenden | |
| UY27322A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| UY27336A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| YU37203A (sh) | Derivati supstituisanih 2-fenilaminoimidazolin-fenil- ketona kao ip antagonisti | |
| EA200600811A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ | |
| AR037517A1 (es) | Derivados de naftiridinas, un proceso para su preparacion, composicion farmaceutica y el uso de los mismos para la preparacion de un medicamento para el tratamiento de una enfermedad inflamatoria | |
| GT199800180A (es) | Derivados de la tienopirimidina y de la tienopiridina utiles como agentes anticancerigenos. | |
| AR045040A1 (es) | Derivados de compuestos espiroazabiciclicos, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos | |
| ECSP034563A (es) | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti-inflamatorios y analgesicos | |
| AR035371A1 (es) | Aminotiazoles, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de un medicamento | |
| AR035235A1 (es) | Derivados heterocicliloxi-,-tioxi- y -aminobenzazol como ligandos de 5-hidroxitriptamina-6, un procedimiento para su preparacion, composicion farmaceutica, y el uso de dichos derivados para la manufactura de un medicamento | |
| AR035603A1 (es) | Derivados de piperazina, composicion farmaceutica que los comprende y el uso de los mismos para la fabricacion de un medicamento como agentes serotonergicos | |
| ATE530187T1 (de) | Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern | |
| UY26919A1 (es) | Derivados de la quinazolina como antagonistas adrenérgicos alfa - 1 | |
| AR033429A1 (es) | Derivados del acido alcoxicarbonilamino-heteroarilcarboxilico, su uso, un procedimiento para prepararlos y composiciones farmaceuticas que los comprenden | |
| AR007108A1 (es) | Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes. | |
| AR037611A1 (es) | Compuestos derivados de amino-tetralina, su uso, un procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
| MXPA04005426A (es) | Derivados de pirazol de anillos fuisionados. | |
| RU2007125660A (ru) | Фенилпиперазиновые производные с сочетанием свойств неполного агонизма к рецепторам дофамина-d2 и ингибирования повторного поглощения серотонина | |
| AR023111A1 (es) | Derivados de sulfonamida utiles como antagonistas del receptor 5-ht7, un procedimiento para su preparacion y composicion farmaceutica que los comprenden | |
| UY27034A1 (es) | Derivados de pirimidina | |
| AR054707A1 (es) | Derivados de octahidropirrolo 3,4-c pirrol, un procedimiento para su preparacion, una composicion farmaceutica y uso del compuesto para la fabricacion de un medicamento | |
| MX9405111A (es) | Nuevos derivados de (1-fenil-1-heterociclil)metanol y(1-fenil-1-heterociclil-metilamina). | |
| AR030946A1 (es) | Derivados de imidazoles sustituidos un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos como agonistas o antagonistas duales de h1 y h3 de histamina | |
| SE9904177D0 (sv) | Novel compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |